Race, hypertensive disorders of pregnancy and outcomes in peripartum cardiomyopathy
- PMID: 38996860
- PMCID: PMC11437515
- DOI: 10.1016/j.ahj.2024.07.002
Race, hypertensive disorders of pregnancy and outcomes in peripartum cardiomyopathy
Abstract
Background: Black women with peripartum cardiomyopathy (PPCM) have a higher prevalence of hypertensive disorders of pregnancy (HDP) and worse clinical outcomes compared with non-Black women. We examined the impact of HDP on myocardial recovery in Black women with PPCM.
Methods: A total of 100 women were enrolled into the Investigation in Pregnancy Associated Cardiomyopathy (IPAC) study. Left ventricular ejection fraction (LVEF) was assessed by echocardiography at entry, 6, and 12-months post-partum (PP). Women were followed for 12 months postpartum and outcomes including persistent cardiomyopathy (LVEF ≤35%), left ventricular assist device, (LVAD), cardiac transplantation, or death were examined in subsets based on race and the presence of HDP.
Results: Black women with HDP were more likely to present earlier compared to Black women without HDP (days PP HDP: 34 ± 21 vs 54 ± 27 days, P = .03). There was no difference in LVEF at study entry for Black women based on HDP, but better recovery with HDP at 6 (HDP: 52 ± 11% vs no HDP: 40 ± 14%, P = .03) and 12-months (HDP:53 ± 10% vs no HDP:40 ± 16%, P = .02). At 12-months, Black women overall had a lower LVEF than non-Black women (P < .001), driven by less recovery in Black women without HDP compared to non-Black women (P < .001). In contrast, Black women with HDP had a similar LVEF at 12 months compared to non-Black women (P = .56).
Conclusions: In women with PPCM, poorer outcomes evident in Black women were driven by women without a history of HDP. In Black women, a history of HDP was associated with earlier presentation and recovery which was comparable to non-Black women.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of interest AEJ has received honoraria from Sanofi and Edwards Lifesciences. All other authors have no Conflicts of Interest to disclose.
Similar articles
-
Importance of Early Diagnosis in Peripartum Cardiomyopathy.Hypertension. 2020 Jan;75(1):91-97. doi: 10.1161/HYPERTENSIONAHA.119.13291. Epub 2019 Nov 11. Hypertension. 2020. PMID: 31707840 Free PMC article.
-
GNB3 C825T Polymorphism and Myocardial Recovery in Peripartum Cardiomyopathy: Results of the Multicenter Investigations of Pregnancy-Associated Cardiomyopathy Study.Circ Heart Fail. 2016 Mar;9(3):e002683. doi: 10.1161/CIRCHEARTFAILURE.115.002683. Circ Heart Fail. 2016. PMID: 26915373 Free PMC article.
-
Clinical Outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy).J Am Coll Cardiol. 2015 Aug 25;66(8):905-14. doi: 10.1016/j.jacc.2015.06.1309. J Am Coll Cardiol. 2015. PMID: 26293760 Free PMC article.
-
Heart failure in pregnancy: what is the long-term impact of pregnancy on cardiac function? A tertiary care centre experience and systematic review.Open Heart. 2021 Aug;8(2):e001587. doi: 10.1136/openhrt-2021-001587. Open Heart. 2021. PMID: 34344721 Free PMC article.
-
Peripartum Cardiomyopathy and Preeclampsia: Overlapping Diseases of Pregnancy.Curr Hypertens Rep. 2018 Jul 3;20(8):69. doi: 10.1007/s11906-018-0868-9. Curr Hypertens Rep. 2018. PMID: 29971645 Review.
References
-
- Arany Z, Elkayam U. Peripartum cardiomyopathy. Circulation 2016;133:1397–1409. - PubMed
-
- Gunderson EP, Croen LA, Chiang V, Yoshida CK, Walton D, Go AS. Epidemiology of peripartum cardiomyopathy: incidence, predictors, and outcomes. Obstetrics & Gynecology 2011;118:583–591. - PubMed
-
- Umesawa M, Kobashi G. Epidemiology of hypertensive disorders in pregnancy: prevalence, risk factors, predictors and prognosis. Hypertens Res 2017;40:213–220. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous